- Viking Therapeutics’ stock rallied after positive early drug study data
- The drug candidate VK2735 showed reductions in liver fat levels
- Shares rose as much as 7% in after-hours trading
Viking Therapeutics Inc. saw a surge in its stock price following the release of promising data from an early stage clinical study. The study showed that the company’s drug candidate, VK2735, was effective in reducing liver fat levels. This positive news caused Viking Therapeutics’ shares to rise by as much as 7% in after-hours trading. The Phase 1 dosing study demonstrated significant reductions in liver fat content and plasma lipid levels after just 28 days of treatment. This is a promising development for the biotech drug developer and has generated excitement among investors.
